Targeting the eosinophil key in severe allergic asthma, studies suggest

The clinical response to anti-IL5/5R drugs mepolizumab and benralizumab appears to be the same in patients whether or not they have a severe allergic component to their asthma, research suggests. A team at Guy’s Severe Asthma Centre in London compared clinical outcomes with the monoclonal antibodies between patients who were also eligible for omalizumab because ...

Already a member?

Login to keep reading.

© 2022 the limbic